Clinical Data

ADA: AstraZeneca hands Structure a win with ‘relatively underwhelming’ GLP-1 pill data

BioSpace

AstraZeneca is pushing its small molecule GLP-1 drug to Phase 3 development for weight control, diabetes and other cardiometabolic conditions despite the asset failing to best one from Structure Thera

Metabolic & GLP-1

Read full story

pharminent June 9, 2026 (Last updated: June 9, 2026)

BioSpace

Metabolic & GLP-1

Read full story

Related Stories

ADA: Boehringer leans on fat mass benefits as obesity bet delivers ‘less competitive’ weight reduction

Otsuka energizes IgA neuropathy space with new Phase 3 Voyxact data

ADC Therapeutics slumps on cancer drug safety scare

You May Have Missed

Alzecure enters collaboration and with Lilly for Alzheimer’s project

ADA: AstraZeneca hands Structure a win with ‘relatively underwhelming’ GLP-1 pill data

GSK pays $10.6B for cancer biotech Nuvalent in industry’s second-biggest buy of the year

ADA: Lilly bests Novo again, takes GLP-1 pill Foundayo to FDA for diabetes approval